Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Neoplasms 22Pancreatic Neoplasms 21Neoplasm Metastasis 12Lung Neoplasms 12Brain Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 7Breast Neoplasms 7Gliosarcoma 6Glioblastoma 6Salivary Gland Neoplasms 5Rectal Neoplasms 5Glioma 5Colorectal Neoplasms 5Colonic Neoplasms 5Astrocytoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Solid Tumors 4Esophageal Neoplasms 4Tongue Neoplasms 3Prostatic Neoplasms 3Oligodendroglioma 3Lymphoma 3Gallbladder Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Hepatocellular 3Bile Duct Neoplasms 3Advanced Cancers 3Advanced Cancer 3

Interventions

Lead 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × EGFR-Mutant Lung Cancer × Erlotinib Hydrochloride × Clear all
NCT01967095 2018-11-13

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
53 enrolled
Thoracic

EGFR-Mutant Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡